A little caution...

I am very excited about Neuren and am extremely hopeful that we will make fast roads to commercialisation. But there needs to a realistic expectation. Much has been posted by “people in the know”….and not so much…

There really does need to be caution with any small company such as Neuren. The FDA meeting to "discuss these latest results" is not until April 2015. This study was a very small trial and will need much more research and a more trials on larger scales before consideration of approval occurs. I have invested in many many up and coming biotech’s and this one is very exciting... however do not be misguided here it will take much much much more research, money and years before NNZ 2655 is available for the market.
The talk of FTD enabling this to be to go direct to market "avoiding phase 3 trials" is very much NOT the case. It will take time and this share will fluctuate over the next few years. The last few days has been very exciting for the share price, it should stablise soon and then hold at a reasonable level. News will assist it to maintain between .11cps and 12.5cps (great scenario) and this is spectacular because it remains a small, unproven and in very much in the early stages of trials.
Goodluck to all and I would NOT be selling unless you are willing to risk not getting back in under .11cps.
Regards,
L